Recent Advances
11/21/16 David Weiner selected as Top
20 Translational Researcher by Nature
Biotechnology
11/14/16 INO-311...
oncology approaches, but their 15%-20% response rates (as monotherapies) 	
		 have led thought leaders to highlight the ne...
Upcoming SlideShare
Loading in …5
×

Company Profile

558 views

Published on

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
558
On SlideShare
0
From Embeds
0
Number of Embeds
82
Actions
Shares
0
Downloads
3
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide
  • Three Phase II studies underway – interim data from two in 2012Three additional Phase I studies to report data by 1H 2012
  • Three Phase II studies underway – interim data from two in 2012Three additional Phase I studies to report data by 1H 2012
  • Three Phase II studies underway – interim data from two in 2012Three additional Phase I studies to report data by 1H 2012
  • (cause 70% of cervical cancers)Powered to detect efficacyStudy timelineLaunched 1Q 2011; enrollment underway Enrollment: 1 – 1 ½ yearsPotential extension to CIN 1; cervical cancer; other anogenital and head & neck cancers; additional HPV types
  • 222,000 deathsWilms' tumor gene 1 (WT1) is overexpressed in the majority (70-90%) of acute leukemias and has been identified as an independent adverse prognostic factor, a convenient minimal residual disease (MRD) marker and potential therapeutic target in acute leukemia.
  • 222,000 deathsWilms' tumor gene 1 (WT1) is overexpressed in the majority (70-90%) of acute leukemias and has been identified as an independent adverse prognostic factor, a convenient minimal residual disease (MRD) marker and potential therapeutic target in acute leukemia.
  • SVR from SOC only for genotype 1 virus: typically 40-50%
  • SVR from SOC only for genotype 1 virus: typically 40-50%
  • Company Profile

    1. 1. Recent Advances 11/21/16 David Weiner selected as Top 20 Translational Researcher by Nature Biotechnology 11/14/16 INO-3112 generates T cell immune responses in patients with HPV-associated head and neck cancer 11/10/16 Zika vaccine protects animals from infection, brain damage and death 10/24/16 FDA requests additional infor- mation for phase III program for VGX- 3100; trial initiation delayed 10/21/16 Inovio CEO selected as 2016 Healthcare Innovator by Philadelphia Business Journal 10/12/16 Inovio expands executive team 9/12/16 Zika vaccine selected as Popular Mechanics’ 2016 Technology Breakthrough 8/29/16 Second human Zika vaccine trial launches in Puerto Rico 8/16/16 Veterinary foot and mouth dis- ease vaccine licensed to Plumbline Life Sciences 8/11/16 Inovio expands positive phase I Ebola vaccine trial Inovio’s T cell activating immunotherapy technology to make transformational step with initiation of phase III for cervical dysplasia and first immuno-oncology combination in partnership with MedImmune/AstraZeneca. Investment Highlights Inovio in final steps to start phase III study for VGX-3100 HPV immunotherapy in cervical pre-cancer in 1H17. Trial package submitted to FDA in September 2016. FDA requested additional device shelf life data, may have other questions; placed program on clinical hold prior to initiation. • First-in-class clinically relevant efficacy achieved in controlled phase II study of high grade cervical pre-cancer (CIN 2/3). • Met primary endpoint for lesion regression and secondary endpoint for viral clearance. • Phase 2b data published in The Lancet is an industry first, demonstrating the correlation of antigen-specific CD8+ T cells (generated in the body) directly to clinical efficacy. • Current surgical procedure is invasive and has been associated with pre-term births; it cannot eliminate the cancer-causing virus from untreated tissue. Major pharma partnership with MedImmune moving toward Inovio’s first immuno- oncology combination study by year end. • Using Inovio’s powerful antigen-specific T cell generation with its broad portfolio of immuno-oncology molecules, which include checkpoint inhibitors. • Acquired exclusive rights to INO-3112 for the treatment of HPV-related cancers. • Upfront payment of $27.5 million; paying all development costs; development and commercial milestone payments amounting to $700 million; up to double- digit tiered royalties on INO-3112 product sales. • Agreement includes joint research to develop two additional DNA-based cancer vaccine products. Inovio’s immunotherapies are designed to treat as well as prevent diseases. • DNA code in the immunotherapy enables the body to produce the desired target antigen(s) relating to a cancer or infectious disease, inducing antigen-specific preventive antibody and therapeutic T-cell immune responses most similar to the body’s natural immune response. • The genetic code is designed to create two strategic capabilities: break the tolerance of the immune system to cancerous cells or generate universal immune responses against multiple unmatched strains of a pathogen such as influenza. The novel SynCon® DNA sequences are patentable. • Potential to be used as monotherapies against early stage or slowly progressing cancers, in combination with third party immuno-oncology products, or in combination with in-house DNA-based monoclonal antibodies (dMAb). Best-in-class in vivo T cell activation positions technology for combination immuno- oncology strategies. • Checkpoint inhibitors have invigorated tremendous enthusiasm for immuno- About the Company NASDAQ INO Recent market price1 $8.33 52-week range $4.50-$11.69 Shares outstanding2 74.0M Market capitalization1 $616.4M Avg. daily vol. (3 mo.)1 1.2M Cash & short term investments2 $119.7M Debt2 $0 Inovio. Taking Immunotherapy to the Next Level 1 November 14, 2016 2 September 30, 2016
    2. 2. oncology approaches, but their 15%-20% response rates (as monotherapies) have led thought leaders to highlight the need for combination therapies including technologies such as cancer vaccines. While checkpoint inhibitors are overcom- ing cancer cells’ ability to hide from killer T cells, there must be more pre-existing killer cells to destroy cancer cells at a higher level. Inovio’s technology has this potential capability. • Robust antigen-specific T cell responses correlated to efficacy in phase II validates technology platform. • Robust killer T cell immune responses reported in 10 evaluable patients with head and neck cancer are a step showing Inovio’s potential to address cancers. • hTERT DNA cancer immunotherapy, relevant to 85% of cancers, generated robust T-cell immune responses, reduced tumors, prevented tumor recurrence, and increased the rate of survival in preclinical studies. DNA-based monoclonal antibody technology application introduces vast clinical and commercial potential. • Using the same core DNA plasmid technology, genetic code enables the body to produce monoclonal antibodies able to provide rapid protection against infectious disease or fight cancers with checkpoint inhibition, tumor blocking pathways, or other cytotoxic mechanisms. • DARPA awarded Inovio and collaborators, including MedImmune, $57M to develop dMAb products against influenza, antibiotic resistant bacteria, and Ebola. Targeting multiple challenging infectious diseases with unmet needs including Ebola, MERS, Zika, HIV, and hepatitis. About $135M in third party grants, including NIH & DARPA. Inovio Vision 2020 highlights the company’s aspiration to have three products filed for marketing approval with the FDA or in phase III by the year 2020 from three development paths: HPV-related pre-cancers, cancer, and infectious diseases. Scientific Advisory Board David B. Weiner, Ph.D., Chairman Executive VP & Director, Wistar Institute Vaccine Center Synthetic vaccine pioneer Anthony Ford-Hutchinson, Ph.D. Former SVP, Merck Vaccines R&D Stanley A. Plotkin, M.D. Emeritus Professor, Wistar & UPenn Principal Vaxconsult Board of Directors Avtar Dhillon, M.D. Chairman of the Board Ex-MDS Healthcare Simon X. Benito Former SVP, Merck Vaccines Angel Cabrera, Ph.D. President, George Mason University Morton Collins, Ph.D. General Partner, Battelle Ventures J. Joseph Kim, Ph.D. President & CEO, Inovio Adel Mahmoud, Ph.D. Former President, Merck Vaccines Professor, Dept. Molecular Biology, Princeton University David B. Weiner, Ph.D. Nancy Wysenski, MBA Former COO of Endo Pharmaceuticals & Vertex Pharmaceuticals Management J. Joseph Kim, Ph.D. President and Chief Executive Officer Ex-Merck Peter Kies Chief Financial Officer Ex-Ernst & Young Niranjan Y. Sardesai, Ph.D. Chief Operating Officer Developed/commercialized products Mark L. Bagarazzi, M.D. Chief Medical Officer Ex-Merck regulatory affairs, vaccines Contact Bernie Hertel VP Investor Relations & Communications Inovio Pharmaceuticals 858 410 3101 bhertel@inovio.com • www.inovio.com This Corporate Profile contains certain forward-looking statements relating to our business, including our plans to develop DNA vaccines and electroporation-based drug and gene delivery technologies.Actual events or results may differ from the expectations set forth herein as a result of a number of factors,including uncertainties inherent in pre-clinical studies,clinical trials and product development programs,including,but not limited to,the fact that pre-clinical and clinical results referenced in this profile may not be indicative of results achievable in other trials or for other indications, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies, our ability to obtain necessary regulatory approvals, capital market conditions and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, our Form 10-Q for the quarter ended September 30, 2016, and other regulatory filings from time to time. Product Milestones Internally Funded Externally Funded Indication Pre-clinical Phase I Phase II Milestone 1H17 Initiate phase III 1Q17 Start IO combo study 2016 Report interim data 1Q17 Start PI/II 2H17 Report phase I study data 2016 Study initiated with NCI 2017 Report data 2016 Publish clinical data in peer-reviewed journal 2016 Report phase I study data 2017 Report P1 data with possible efficacy signals Cervical Dysplasia Therapeutic HPV-Related Cancers Therapeutic Prostate Cancer Therapeutic hTERT (antigen) Therapeutic Hepatitis B Therapeutic Hepatitis C Therapeutic HIV Preventive/Therapeutic Ebola Preventive MERS Preventive Zika Preventive

    ×